Predicting the risk of bone metastasis in prostate cancer

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 3-11

  Briganti, Alberto ^a   Suardi, Nazareno ^a   Gallina, Andrea ^a   Abdollah, Firas ^a   Novara, Giacomo ^b   Ficarra, Vincenzo ^b   Montorsi, Francesco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bone metastasis; Gleason score; Prostate cancer; PSA kinetics; PSA level; Risk factor

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACTIVIN A; BONE MORPHOGENETIC PROTEIN 6; BONE SPECIFIC ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CARBOXY TERMINAL PYRIDINOLINE CROSS LINKED TELOPEPTIDE PART OF TYPE 1 COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; CHROMOGRANIN A; ELONGATION FACTOR 1ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH DIFFERENTIATION FACTOR 15; MATRILYSIN; OSTEOPROTEGERIN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; PROCOLLAGEN TYPE 1 CARBOXY TERMINAL PROPEPTIDE; PROSTASOME ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC IMAGING; DISEASE MARKER; DISTANT METASTASIS; EVIDENCE BASED MEDICINE; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; LOCAL THERAPY; MULTIMODALITY CANCER THERAPY; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

BONE METASTASIS; GLEASON SCORE; PROSTATE CANCER; PSA KINETICS; PSA LEVEL; RISK FACTOR;

BONE NEOPLASMS; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK;

EID: 84887043720     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.07.001     Document Type: Review

References (83)

1. Center M.M., Jemal A., Lortet-Tieulent J., et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61:1079-1092.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Roehrborn C.G., Black L.K. The economic burden of prostate cancer. BJU Int 2011, 108:806-813.
4. Scosyrev E., Wu G., Mohile S., Messing E.M. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012, 118:5768-5776.
5. Norgaard M., Jensen A.O., Jacobsen J.B., Cetin K., Fryzek J.P., Sorensen H.T. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999-2007). J Urol 2010, 184:162-167.
6. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
7. Hess K.R., Varadhachary G.R., Taylor S.H., et al. Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633.
8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
9. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
10. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
11. Ibrahim T., Flamini E., Mercatali L., Sacanna E., Serra P., Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 116:1406-1418.
12. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
13. Hagiwara M., Delea T.E., Saville M.W., Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 2012, 16:23-27.
14. Oglesby A, Pockett R, McEwan P, Chung K. Hospital burden of disease associated with metastatic bone disease and skeletal-related events in patients with breast cancer and prostate cancer in the United Kingdom. In: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008. Abstract PCN54.
15. Tombal B., Lecouvet F. Modern detection of prostate cancer's bone metastasis: is the bone scan era over?. Adv Urol 2012, 2012:893193.
16. Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology guidelines on prostate cancer, 2012. Available at: http://www.uroweb.org.
17. Greene K.L., Albertsen P.C., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182:2232-2241.
18. Horwich A., Parker C., Bangma C., Kataja V. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v129-v133.
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
20. Abuzallouf S., Dayes I., Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004, 171:2122-2127.
21. Salonia A., Gallina A., Camerota T.C., et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology 2006, 68:362-366.
22. Tanaka N., Fujimoto K., Shinkai T., et al. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ≤20 ng/ml and Gleason score of ≤6 at the initial stage of diagnosis. Jpn J Clin Oncol 2011, 41:1209-1213.
23. Lee S.H., Chung M.S., Park K.K., Yom C.D., Lee D.H., Chung B.H. Is it suitable to eliminate bone scan for prostate cancer patients with PSA
24. McArthur C., McLaughlin G., Meddings R.N. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br J Radiol 2012, 85:390-394.
25. Briganti A., Passoni N., Ferrari M., et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010, 57:551-558.
26. Dotan Z.A., Bianco F.J., Rabbani F., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005, 23:1962-1968.
27. Alibhai S.M., Gogov S., Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006, 60:201-215.
28. Okotie O.T., Aronson W.J., Wieder J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004, 171:2260-2264.
29. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
30. Rogers C.G., Khan M.A., Craig M.M., Veltri R.W., Partin A.W. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004, 101:2549-2556.
31. Choueiri T.K., Dreicer R., Paciorek A., Carroll P.R., Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008, 179:906-910.
32. Keto C.J., Aronson W.J., Terris M.K., et al. Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol 2012, 10.1016/j.eururo.2012.11.052.
33. Abouassaly R., Paciorek A., Ryan C.J., Carroll P.R., Klein E.A. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 2009, 115:4470-4476.
34. Cooperberg M.R., Pasta D.J., Elkin E.P., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005, 173:1938-1942.
35. Cooperberg M.R., Broering J.M., Carroll P.R. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009, 101:878-887.
36. Boorjian S.A., Thompson R.H., Tollefson M.K., et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011, 59:893-899.
37. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005, 23:2918-2925.
38. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011, 117:2077-2085.
39. Prensner J.R., Rubin M.A., Wei J.T., Chinnaiyan A.M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012, 4. 127rv3.
40. Zhao H., Han K.L., Wang Z.Y., et al. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors. Med Sci Monit 2011, 17:CR626-CR633.
41. Rasch-Isla M.A., Catano Catano J.G. Usefulness of bone-specific alkaline phosphatase for bone metastases detection in prostate cancer. Arch Esp Urol 2004, 57:693-698.
42. Cook R.J., Coleman R., Brown J., et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006, 12:3361-3367.
43. Deligezer U., Yaman F., Darendeliler E., et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta 2010, 411:1452-1456.
44. Zissimopoulos A., Stellos K., Matthaios D., et al. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON 2009, 14:463-472.
45. Zissimopoulos A., Bantis A., Stellos K., Petrakis G., Matthaios D. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. J BUON 2008, 13:69-74.
46. Zissimopoulos A., Stellos C., Petrakis G., Baziotis N. Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma. Hell J Nucl Med 2004, 7:162-167.
47. Klepzig M., Jonas D., Oremek G.M. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res 2009, 29:671-673.
48. Lein M., Wirth M., Miller K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007, 52:1381-1387.
49. Thurairaja R., Iles R.K., Jefferson K., McFarlane J.P., Persad R.A. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 2006, 76:67-71.
50. Koopmans N., de Jong I.J., Breeuwsma A.J., van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007, 178:849-853.
51. Koizumi M., Yonese J., Fukui I., Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001, 87:348-351.
52. Leeming D.J., Hegele A., Byrjalsen I., et al. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008, 17:1269-1276.
53. Kamiya N., Suzuki H., Yano M., et al. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 2010, 75:1446-1451.
54. Kataoka A., Yuasa T., Kageyama S., et al. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol) 2006, 18:480-484.
55. Ozu C., Nakashima J., Horiguchi Y., Oya M., Ohigashi T., Murai M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008, 15:419-422.
56. Hegele A., Wahl H.G., Varga Z., et al. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 2007, 99:330-334.
57. Kamiya N., Suzuki H., Endo T., et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol 2011, 16:366-372.
58. Chen H.X., Li H.Z., Li H.J., Shi B.B., Jin W., Cheng X.Q. Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer. Zhonghua Wai Ke Za Zhi 2007, 45:412-414.
59. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791.
60. Helo P., Cronin A.M., Danila D.C., et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with Cell Search assay and association with bone metastases and with survival. Clin Chem 2009, 55:765-773.
61. Danila D.C., Heller G., Gignac G.A., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:7053-7058.
62. Zhao Z., Ma W., Zeng G., Qi D., Ou L., Liang Y. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy. Prostate 2012, 72:270-279.
63. Xu T., Chen X., Wang X.F., et al. Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications. Beijing Da Xue Xue Bao 2004, 36:164-168.
64. Larsson A., Ronquist G., Wulfing C., et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 2006, 24:195-200.
65. Zissimopoulos A., Bantis A., Sountoulides P., et al. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hell J Nucl Med 2009, 12:234-237.
66. Lehrer S., Diamond E.J., Mamkine B., Droller M.J., Stone N.N., Stock R.G. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005, 95:961-962.
67. Selander K.S., Brown D.A., Sequeiros G.B., et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007, 16:532-537.
68. Szarvas T., Becker M., Vom D.F., et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 2011, 128:1486-1492.
69. Incorvaia L., Badalamenti G., Rini G., et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007, 27:1519-1525.
70. Leto G., Incorvaia L., Badalamenti G., et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006, 23:117-122.
71. Shariat S.F., Anwuri V.A., Lamb D.J., Shah N.V., Wheeler T.M., Slawin K.M. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004, 22:1655-1663.
72. Okegawa T., Kinjo M., Nutahara K., Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006, 13:1197-1201.
73. Shariat S.F., Roehrborn C.G., McConnell J.D., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007, 25:349-355.
74. Rehman I., Evans C.A., Glen A., et al. ITRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PLoS One 2012, 7:e30885.
75. Nelson E.C., Evans C.P., Pan C.X., Lara P.N. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol 2007, 25:393-399.
76. Joerger M., Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012, 192:197-223.
77. Saad F., Pantel K. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. Future Oncol 2012, 8:321-331.
78. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
79. Mason M.D., Sydes M.R., Glaholm J., et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007, 99:765-776.
80. Nelson J.B., Love W., Chin J.L., et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113:2478-2487.
81. AstraZeneca. AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer. 2012. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN.
82. Smith M.R., Saad F., Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
83. Smith M.R., Saad F., Shore N., et al. Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J Clin Oncol 2012, 30. [Abstract 6].